The company advances its pipeline leveraging its proprietary Alector Brain Carrier (ABC) platform, which enhances drug delivery to the brain and is designed to enable peripheral dosing adaptable across multiple drug modalities including antibodies, enzymes, and siRNA. Alector has a strategic collaboration agreement with GlaxoSmithKline for the development and commercialization of progranulin-elevating monoclonal antibodies.
Cyborg Score Rationale
The company's stock outlook has become unfavorable due to the failure of the INFRONT-3 trial of latozinemab to meet its primary endpoint. However, Alector has $256M in cash as of December 31, 2025, expected to fund operations at least through 2027, with key milestones including a futility analysis for PROGRESS-AD in 1H 2026.
Top Insights
The INFRONT-3 trial failure indicates significant translational biology risks that negatively impact the company's therapeutic promise.
Q4 2025 quarterly revenue fell to $6.2M with a net loss of $37.3M, reflecting transition from partnership revenue to internal programs.
Key 2026-2027 milestones include IND timelines for ABC-enabled candidates AL137, AL050, and AL064 targeting regulatory filings.
Limited target markets and competition from larger biotech firms increase risks of dilution, delays, and challenges in attracting resources despite strong cash position.